...
首页> 外文期刊>Journal of Pain Research >The increased release of amino acid neurotransmitters of the primary somatosensory cortical area in rats contributes to remifentanil-induced hyperalgesia and its inhibition by lidocaine
【24h】

The increased release of amino acid neurotransmitters of the primary somatosensory cortical area in rats contributes to remifentanil-induced hyperalgesia and its inhibition by lidocaine

机译:大鼠主要体感皮层区域氨基酸神经递质的释放增加,导致瑞芬太尼引起痛觉过敏,并被利多卡因抑制

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Studies have confirmed that activation of the neurons of primary somatosensory cortex (S1) is involved in the process of remifentanil (Remi)-induced hyperalgesia (RIH), which can be suppressed by lidocaine (Lido). A total intravenous anesthesia model of rats mimicking clinical Remi-based anesthesia was set up to explore the release of amino acid neurotransmitters of S1 cortex in RIH and its inhibition by Lido in this study. Materials and methods: Sprague Dawley rats were randomly divided into the following four groups: propofol (Pro), Remi, Remi combined Lido, and Lido groups. Mechanical hyperalgesia was evaluated by von Frey test; the amino acid neurotransmitters in the microdialysates of S1 area were detected by high-performance liquid chromatography (HPLC)-fluorescence, and conventional protein kinase C (cPKC)γ levels in the whole-cell lysates and membrane lipid rafts (MLRs) were determined by Western blotting. Results: The von Frey test showed that co-administration of Lido significantly inhibited a Remi-induced decrease in the threshold of the paw withdrawal response in Remi group at 2?h postinfusion. Meanwhile, the Remi-induced increases in both the excitatory and inhibitory amino acid releases in S1 were suppressed by co-administrating Lido within 5?h postinfusion. Western blotting showed that the increased cPKCγ level in the membrane lipid rafts (MLR) induced by Remi was also inhibited by Lido. Conclusion: The increased release of amino acid neurotransmitters and the translocation of cPKCγ in MLR suggest the activation of S1 neurons, which may be one of the mechanisms underlying RIH. Lido reduces the release of amino acid neurotransmitters in S1 neurons and the translocation of cPKCγ in MLRs after stopping Remi, which may be one of its antihyperalgesic mechanisms.
机译:背景:研究已经证实,瑞芬太尼(Remi)诱导的痛觉过敏(RIH)的过程涉及初级体感皮层(S1)的神经元的激活,利多卡因(Lido)可以抑制这一过程。建立了一种模拟基于临床Remi麻醉的大鼠全静脉麻醉模型,以研究RIH中S1皮质的氨基酸神经递质的释放及其对Lido的抑制作用。材料和方法:将Sprague Dawley大鼠随机分为以下四组:异丙酚(Pro),Remi,Remi合并Lido和Lido组。机械性痛觉过敏通过von Frey检验进行评估;通过高效液相色谱(HPLC)-荧光检测S1区域微透析液中的氨基酸神经递质,并通过以下方法测定全细胞裂解液和膜脂质筏(MLR)中常规的蛋白激酶C(cPKC)γ水平蛋白质印迹。结果:von Frey试验表明,在输注后2小时,丽多组的共同给药显着抑制了瑞米诱导的爪撤缩反应阈值的降低。同时,通过在输注后5h内同时服用Lido,可以抑制Remi诱导的S1兴奋性和抑制性氨基酸释放的增加。蛋白质印迹显示,Lido也可抑制Remi引起的膜脂质筏(MLR)中cPKCγ水平的升高。结论:MLR中氨基酸神经递质的释放增加和cPKCγ的易位提示S1神经元的激活,这可能是RIH的机制之一。丽都可在停止Remi后减少S1神经元中氨基酸神经递质的释放以及cLRCγ在MLR中的移位,这可能是其抗痛觉过敏机制之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号